US · AIXC
AIxCrypto Holdings, Inc.
- Sector
- Healthcare · Medical - Pharmaceuticals
- Headquarters
- Carlsbad, CA 92008
- Website
- qlgntx.com
Price · as of 2024-12-31
$1.48
Market cap 5.88M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $1,665.00 | ||||
| 2021 | $300.00 | $368.04 | $0.38 | $0.00 | $0.00 |
| 2022 | $54.00 | $884.33 | |||
| 2023 | $20.25 | ||||
| 2024 | $3.12 |
AI valuation
Our deep-learning model estimates AIxCrypto Holdings, Inc.'s (AIXC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.48
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AIXC | AIxCrypto Holdings, Inc. | $1.48 | 5.88M | — | — | — | — | -0.18 | 0.42 | — | 0.01 | — | 0.42 | 0.00% | — | — | -2140.54% | -3863.24% | -183.32% | 0.00 | -6.34 | 2.33 | 1.59 | 0.22 | -8673.00% | — | -3859.00% | -560.87% | -3.15 | -4242.60% | 0.00% | 0.00% | 183.67% | 0.01 | 0.01 | — | -39.80 |
| ATGL | Alpha Technology Group Li… | $17.03 | 259.92M | +9% | -39% | — | -3% | -47.50 | 136.11 | 452.23 | -48.01 | -4.37 | 136.11 | -524.82% | -782.06% | -951.99% | -184.54% | -923.32% | -148.46% | 0.22 | -50.63 | 3.25 | 3.24 | 0.37 | 108611.00% | -4025.00% | -2930.00% | -0.42% | -1.33 | -225.89% | 0.00% | 0.00% | 0.00% | -57.38 | -238.09 | 448.78 | 186.06 |
| AUID | authID Inc. | $1.66 | 20.17M | +3,253% | +23% | — | — | -3.65 | 4.53 | 58.81 | -3.12 | — | 7.32 | 100.00% | -1656.46% | -1610.63% | -115.55% | -449.78% | -95.56% | 0.02 | -300.11 | 3.41 | 3.04 | 0.59 | -5556.00% | 36586.00% | 3933.00% | -22.42% | -3.93 | -358.03% | 0.00% | 0.00% | 0.00% | -2.99 | -3.76 | 49.52 | -8.93 |
| CTOR | Citius Oncology, Inc. | $1.12 | 98.87M | — | — | — | — | -3.31 | 1.83 | — | -3.49 | -24.86 | 1.83 | 0.00% | — | — | -54.42% | -49.69% | -26.72% | 0.08 | -107.89 | 0.56 | 0.08 | 0.01 | 1333.00% | — | -444673.00% | -6.69% | -0.11 | -11.60% | 0.00% | 0.00% | 4.78% | -3.48 | -14.92 | — | -1.04 |
| CWD | CaliberCos Inc. | $1.22 | 1.42M | +6,039% | +274% | — | +2,390% | -11.67 | -19.91 | 4.90 | -46.23 | -27.24 | -19.91 | 48.15% | -26.04% | -38.69% | 430.86% | -9.67% | -10.60% | -6.49 | -2.45 | 1.81 | 1.49 | -11.13 | 4286.00% | -4379.00% | -10296.00% | 0.22% | 0.05 | 0.40% | 0.00% | 0.00% | 50.42% | -24.79 | 594.75 | 6.46 | 1.02 |
| IMXI | International Money Expre… | $15.78 | 468.96M | +369% | -48% | -27% | -7% | 7.85 | 3.42 | 0.70 | 4.72 | 79.98 | 8.73 | 89.64% | 14.43% | 8.93% | 41.43% | 43.05% | 11.32% | 1.35 | 8.09 | 1.96 | 1.58 | 0.47 | 982.00% | -1.00% | -8234.00% | 5.00% | 0.35 | 14.81% | 0.00% | 0.00% | 16.27% | 5.40 | 22.22 | 0.78 | 4.11 |
| JG | Aurora Mobile Limited | $7.55 | 45.3M | +527% | -24% | — | — | -60.39 | 6.02 | 1.29 | -544.64 | — | 24.97 | 66.11% | -3.13% | -2.23% | -9.57% | 29.67% | -1.86% | 0.31 | -75.01 | 0.71 | 0.66 | 172.52 | -8856.00% | 894.00% | -11932.00% | 0.87% | 0.03 | -10.67% | 0.00% | 0.00% | 0.63% | -31.35 | 87.18 | 0.98 | -2.30 |
| OLB | The OLB Group, Inc. | $0.66 | 1.77M | +239,686% | -19% | — | +43,505% | -0.22 | 0.77 | 0.19 | -0.35 | — | -0.50 | -5.94% | -90.95% | -87.43% | -145.64% | -148.58% | -69.27% | 0.12 | -254.16 | 0.08 | 0.08 | -0.04 | -6021.00% | -5800.00% | -41835.00% | -105.88% | -0.28 | -33.09% | 0.00% | 0.00% | 0.00% | -0.24 | -1.08 | 0.22 | -10.18 |
About AIxCrypto Holdings, Inc.
AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.
- CEO
- Kevin A. Richardson
- Employees
- 0
- Beta
- 0.34
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.48) − 1 = — (DCF, example).